Identification of eligible patients

Inclusion: Stage I-III colon/rectal cancer, treated with curative intent, over 18 years, speaks English.

Exclusion: Psychological and cognitive difficulties, too unwell, previous malignancies, metastatic cancer at time of recruitment, enrolled in a conflicting trial.

Approach eligible patients (N=250)

Consent patient and register (N=200)

Patient refusals (collect reason for refusal)

Baseline questionnaire

Measure: BSI-18, DT, CaSUN, EORTQ CLQ CR-30 and CR-29, demographics and medical records

Randomise patients

Intervention arm (N=100)
Information provision at randomisation
DVD, Booklet and Question prompt List

Usual Care arm (N=100)
Care provided according to treating centre/ practitioners’ usual practice. Key elements of the intervention will not be provided for the duration of the study.

Nurse-led end of treatment session
1-2 weeks after randomisation
- Normalise end of treatment concerns
- Tailored, evidence-based advice
- Referrals to multidisciplinary team members as necessary
- Discuss survivorship care plan and follow-up
- Coaching
- Referral to peer support program

Survivorship care plan sent to GP and cancer specialists

Nurse-led telephone follow-up calls
1, 3 and 7 weeks after randomisation
- Normalise end of treatment concerns
- Discuss previously identified needs
- Screen for distress, unmet needs
- Encourage adherence to self-care strategies
- Promote shared care/ GP involvement

Follow up 1 questionnaire
8 weeks after randomisation for usual care or 1st intervention session for SurvivorCare (N=90 per arm, 10% attrition from Baseline)
Measures: BSI-18, DT, CaSUN, EORTQ CLQ CR-30 and CR-29

Follow up 2 questionnaire
6 months after randomisation for usual care or 1st intervention session for SurvivorCare
Measures: BSI-18, DT, CaSUN, EORTQ CLQ CR-30 and CR-29